We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA WARNS WYETH ABOUT CGMP VIOLATIONS

FDA WARNS WYETH ABOUT CGMP VIOLATIONS

June 6, 2006

The FDA has issued a warning letter to Wyeth Pharmaceuticals citing current good manufacturing practice (cGMP) violations ranging from impurities in drugs to improper cleaning of packing machines at its Guayama, Puerto Rico, facility.

The letter, sent May 8 and posted on the FDA's website May 30, follows up on an inspection conducted between Nov. 7 and Dec. 15, 2005. It notes that the facility was not only outside of cGMP regulations but also failed to comply with new drug application -- field alert reporting requirements by sending out notices five months late. Inadequate efforts to correct the identified errors were also noted.

In one case, the letter states, Wyeth made no effort to identify the cause of an impurity until the issue was raised in the inspection, which "raises serious concerns regarding the timeliness of your investigations." The letter points out that although the investigation had been going on for several months, the affected drug, Triphasil 21 and 28 tablets, remained in the market. However, since the date the letter was sent Wyeth has recalled the product at the wholesale level, according to company spokesman Doug Petkus.

Maintenance of the facility's packaging equipment was also questioned by the FDA, with a "screw and two washers" found in one shipped bottle and "ejector pins from the filling/packaging line" found in another. The letter goes on to point out the neither the "cleaning procedures nor the line clearance inspections were able to detect that the affected equipment was missing some of its parts." Other instances cited by the letter include drugs not being cleaned out of the filler machines.

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing